Charles Schwab’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $111M | Buy |
462,509
+21,999
| +5% | +$4.82M | 0.01% | 729 |
|
|
2026
Q1 | $83.3M | Buy |
440,510
+16,220
| +4% | +$2.83M | 0.01% | 824 |
|
|
2025
Q4 | $72.1M | Sell |
424,290
-43,193
| -9% | -$6.62M | 0.01% | 912 |
|
|
2025
Q3 | $61.6M | Sell |
467,483
-47,592
| -9% | -$5.71M | 0.01% | 1022 |
|
|
2025
Q2 | $54.7M | Sell |
515,075
-100,642
| -16% | -$10.9M | 0.01% | 1053 |
|
|
2025
Q1 | $76.4M | Buy |
615,717
+200
| +0% | +$26.1K | 0.01% | 797 |
|
|
2024
Q4 | $75.8M | Buy |
615,517
+83,807
| +16% | +$9.88M | 0.01% | 817 |
|
|
2024
Q3 | $59.2M | Buy |
531,710
+42,587
| +9% | +$4.67M | 0.01% | 998 |
|
|
2024
Q2 | $52.2M | Buy |
489,123
+29,179
| +6% | +$3.21M | 0.01% | 1041 |
|
|
2024
Q1 | $55.4M | Sell |
459,944
-45,710
| -9% | -$5.6M | 0.01% | 969 |
|
|
2023
Q4 | $62.2M | Sell |
505,654
-8,324
| -2% | -$1.04M | 0.02% | 822 |
|
|
2023
Q3 | $66.5M | Buy |
513,978
+46,702
| +10% | +$6.22M | 0.02% | 712 |
|
|
2023
Q2 | $57.9M | Buy |
467,276
+20,636
| +5% | +$2.78M | 0.02% | 776 |
|
|
2023
Q1 | $65.4M | Buy |
446,640
+23,963
| +6% | +$3.54M | 0.02% | 660 |
|
|
2022
Q4 | $67.3M | Buy |
422,677
+20,797
| +5% | +$3.05M | 0.02% | 638 |
|
|
2022
Q3 | $53.6M | Buy |
401,880
+44,739
| +13% | +$6.8M | 0.02% | 713 |
|
|
2022
Q2 | $55.7M | Buy |
357,141
+10,415
| +3% | +$1.6M | 0.02% | 685 |
|
|
2022
Q1 | $54M | Buy |
346,726
+12,733
| +4% | +$1.85M | 0.02% | 824 |
|
|
2021
Q4 | $42.6M | Buy |
333,993
+15,435
| +5% | +$2.03M | 0.01% | 1016 |
|
|
2021
Q3 | $41.5M | Sell |
318,558
-4,558
| -1% | -$689K | 0.01% | 1007 |
|
|
2021
Q2 | $57.4M | Buy |
323,116
+37,740
| +13% | +$6.54M | 0.02% | 777 |
|
|
2021
Q1 | $46.9M | Buy |
285,376
+7,984
| +3% | +$1.31M | 0.02% | 877 |
|
|
2020
Q4 | $45.8M | Buy |
277,392
+5,624
| +2% | +$838K | 0.02% | 820 |
|
|
2020
Q3 | $38.8M | Sell |
271,768
-86,589
| -24% | -$10.7M | 0.02% | 794 |
|
|
2020
Q2 | $39.5M | Sell |
358,357
-126,505
| -26% | -$14M | 0.02% | 722 |
|
|
2020
Q1 | $48.4M | Sell |
484,862
-54,308
| -10% | -$7.02M | 0.03% | 539 |
|
|
2019
Q4 | $80.5M | Buy |
539,170
+57,710
| +12% | +$7.85M | 0.04% | 408 |
|
|
2019
Q3 | $61.7M | Buy |
481,460
+24,234
| +5% | +$3.25M | 0.04% | 478 |
|
|
2019
Q2 | $65.2M | Buy |
457,226
+9,797
| +2% | +$1.32M | 0.04% | 446 |
|
|
2019
Q1 | $64M | Buy |
447,429
+3,099
| +0.7% | +$404K | 0.04% | 428 |
|
|
2018
Q4 | $55.1M | Buy |
444,330
+27,247
| +7% | +$4.04M | 0.04% | 409 |
|
|
2018
Q3 | $70.1M | Buy |
417,083
+156,315
| +60% | +$26.9M | 0.05% | 383 |
|
|
2018
Q2 | $44.9M | Buy |
260,768
+42,463
| +19% | +$6.94M | 0.03% | 558 |
|
|
2018
Q1 | $33M | Buy |
218,305
+11,355
| +5% | +$1.67M | 0.03% | 690 |
|
|
2017
Q4 | $27.9M | Buy |
206,950
+9,856
| +5% | +$1.37M | 0.02% | 745 |
|
|
2017
Q3 | $28.8M | Buy |
197,094
+11,428
| +6% | +$1.73M | 0.03% | 663 |
|
|
2017
Q2 | $28.9M | Buy |
185,666
+10,446
| +6% | +$1.6M | 0.03% | 614 |
|
|
2017
Q1 | $25.4M | Buy |
175,220
+9,693
| +6% | +$1.26M | 0.03% | 673 |
|
|
2016
Q4 | $18M | Buy |
165,527
+7,469
| +5% | +$832K | 0.02% | 816 |
|
|
2016
Q3 | $19.2M | Sell |
158,058
-96,273
| -38% | -$13M | 0.02% | 703 |
|
|
2016
Q2 | $35.9M | Buy |
254,331
+54,790
| +27% | +$8.08M | 0.05% | 410 |
|
|
2016
Q1 | $26.1M | Buy |
199,541
+13,644
| +7% | +$1.7M | 0.03% | 510 |
|
|
2015
Q4 | $26.1M | Buy |
185,897
+23,624
| +15% | +$3.27M | 0.04% | 491 |
|
|
2015
Q3 | $21.6M | Buy |
162,273
+18,359
| +13% | +$3.16M | 0.03% | 528 |
|
|
2015
Q2 | $25.3M | Buy |
143,914
+36,544
| +34% | +$6.56M | 0.04% | 476 |
|
|
2015
Q1 | $18.6M | Buy |
107,370
+11,045
| +11% | +$1.9M | 0.03% | 596 |
|
|
2014
Q4 | $15.8M | Buy |
96,325
+8,233
| +9% | +$1.37M | 0.02% | 605 |
|
|
2014
Q3 | $14.1M | Sell |
88,092
-16,185
| -16% | -$2.49M | 0.02% | 613 |
|
|
2014
Q2 | $15.3M | Buy |
104,277
+3,026
| +3% | +$420K | 0.03% | 571 |
|
|
2014
Q1 | $14M | Buy |
101,251
+9,099
| +10% | +$1.37M | 0.03% | 596 |
|
|
2013
Q4 | $11.7M | Buy |
92,152
+7,302
| +9% | +$756K | 0.02% | 628 |
|
|
2013
Q3 | $7.74M | Buy |
84,850
+11,181
| +15% | +$902K | 0.02% | 804 |
|
|
2013
Q2 | $5.14M | Buy |
+73,669
| New | +$4.5M | 0.01% | 1025 |
|
Other funds holding JAZZ
Charles Schwab's JAZZ Position: Q2 2026 in Review
Charles Schwab increased its Jazz Pharmaceuticals (JAZZ) stake by 5% in Q2 2026, buying an estimated $4.82M and bringing the position to 462,509 shares worth $111M. The position accounts for 0.01% of the portfolio, ranked #729.
Charles Schwab first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Charles Schwab held 462,509 shares of Jazz Pharmaceuticals worth $111M as of Q2 2026.
- Charles Schwab bought 21,999 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.82M.
- Jazz Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #729 holding.
- Charles Schwab first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.